Predictors of Anti-TNF Therapy Failure among Inflammatory Bowel Disease (IBD) Patients in Saudi Arabia: A Single-Center Study

Background: The advent of monoclonal antibodies (mAbs) has revolutionized the management of many immune-mediated diseases such as inflammatory bowel disease (IBD). Infliximab and adalimumab were the first mAbs approved for the management of IBD, and are still commonly prescribed for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Alharbi, Othman, Aljebreen, Abdulrahman M., Azzam, Nahla A., Almadi, Majid A., Saeed, Maria, HajkhderMullaissa, Baraa, Asiri, Hassan, Almutairi, Abdullah, AlRuthia, Yazed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321911/
https://www.ncbi.nlm.nih.gov/pubmed/35887921
http://dx.doi.org/10.3390/jcm11144157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321911/
https://www.ncbi.nlm.nih.gov/pubmed/35887921
http://dx.doi.org/10.3390/jcm11144157

Ejemplares similares